More about
Peptide Fragment
News
October 02, 2019
2 min read
Save
FDA approves sacubitril/valsartan for pediatric HF
Novartis announced that sacubitril/valsartan has been approved by the FDA for the treatment of children aged 1 year and older with symptomatic HF and systemic left ventricular systolic dysfunction.